4. CEL-SCI Corporation (NYSE:CVM)
CEL-SCI Corporation is one of the most polarizing names in the biotech sector, and that polarization is precisely what keeps it alive in market conversations. In an industry where many companies fade into obscurity after setbacks, CVM has demonstrated a kind of resilience that is rare—and in some cases, investable. The company’s immunotherapy platform, particularly its focus on cancer treatment, continues to generate debate, skepticism, and persistent interest all at once.
At the center of the story is its flagship immunotherapy approach, which aims to stimulate the immune system in a way that enhances survival outcomes without introducing the toxicity commonly associated with traditional cancer treatments. This positioning aligns with one of the most important long-term trends in healthcare: the shift toward targeted and immune-based therapies. Management has consistently reinforced its belief in the platform, emphasizing its goal of delivering “meaningful survival benefits with a favorable safety profile,” a message that continues to resonate with a niche but dedicated investor base.
From a market perspective, CVM behaves less like a traditional biotech stock and more like a sentiment-driven instrument. It is frequently subject to sharp spikes, often fueled by retail participation, short interest dynamics, and renewed speculation around clinical or regulatory updates. This creates an environment where volatility is not just expected—it is part of the appeal. Stocks like CEL-SCI often become battlegrounds between skeptics and believers, and when momentum shifts, the resulting moves can be dramatic. For investors searching for “biotech stocks with short squeeze potential,” CVM remains firmly in that category, not because it is predictable, but because it is persistently unpredictable.
Click next to see the following stock...
